Arbutus to Present at Jefferies London Healthcare Conference
08 Noviembre 2023 - 6:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the
“Company”), a clinical-stage biopharmaceutical company leveraging
its extensive virology expertise to develop a cure for people with
chronic hepatitis B virus (cHBV) infection, today announced that
the Arbutus management team will participate in and host one-on-one
meetings at the following investor conference:
Jefferies London Healthcare
Conference: Formal presentation on Wednesday, November 15,
2023 at 11:30 am GMT / 6:30 am EDT.
To access the live webcast of the presentation
please visit:
https://investor.arbutusbio.com/events-presentations. An
archived replay of the webcast will be available on the Arbutus
website for a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to identify and develop novel therapeutics with
distinct mechanisms of action, which can be combined to provide a
functional cure for patients with chronic hepatitis B virus (cHBV).
We believe the key to success in developing a functional cure
involves suppressing HBV DNA, reducing surface antigen, and
boosting HBV-specific immune responses. Our pipeline of internally
developed, proprietary compounds includes an RNAi therapeutic,
imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran
has generated meaningful clinical data demonstrating an impact on
both surface antigen reduction and reawakening of the HBV-specific
immune response. Imdusiran is currently in two Phase 2a combination
clinical trials. AB-101 is currently being evaluated in a Phase
1a/1b clinical trial. Additionally, we have identified compounds in
our internal PD-L1 portfolio that could also be used in oncology
indications. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. CaperelliVice President, Investor RelationsPhone:
215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Arbutus Biopharma (NASDAQ:ABUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024